Global Breast Cancer Market is anticipated to grow at a CAGR of 9.2% by 2023

pune, India, 2017-Jul-24 — /EPR Network/ —Breast cancer is one of the major type of cancer in women. To ensure the effective treatment of the patient early stages diagnosis of the breast cancer is important. According to WHO, 200,000 new cases are diagnosed worldwide and the number will increased in the coming future. Different types of treatments are available but there is no absolute treatment. Global breast cancer market is driven by increasing prevalence of breast cancer which is due to adoption of unhealthy lifestyle, genetic profile of the patients and continuous exposure to harmful radiations.

Increasing government support and awareness also contributed in the growth of the market. But side effect associated with the therapy and high cost of treatment has hampered the growth of the market.

Global breast cancer market is expected to grow at a CAGR of 9.2% during forecasted period 2017-2023.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/1379

Major Key Players

• Pfizer (US),
• Novartis AG (Switzerland),
• Oncogenex (US),
• Apthera Inc (UK),
• BioNumerik Pharmaceuticals (US),
• Oncothyreon Inc (US),
• Astellas (Japan),
• Bipar Sciences (US),
• Puma Biotechnology (US),
• Sanofi S.A. (US),
• Eli Lilly and Company (US),

AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), Bayer AG (Germany)

Pfizer is among the world’s largest pharmaceutical companies headquartered in US. In March 2017, company has got FDA approval of IBRANCE for the first line HR+, HER2- metastatic breast cancer. It is the only cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor approved by the FDA as a first line therapy. In 2016, Pfizer has acquired Medivation to increase its oncology market.

AstraZeneca is an Anglo–Swedish multinational pharmaceutical company headquarters in UK.  In 2017, company has got approval for three new drugs. Lynparza is one of three new drugs which is PARP inhibitors. This drug has shown a most promising results in Phase III clinical trials and may generate $1.2 billion by 2020.

Novartis AG is one of the largest Swiss pharmaceutical company. In 2017, company has got FDA approval for Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer with the combination of any aromatase inhibitor. GlaxoSmithKline is the world sixth largest pharmaceutical company headquartered in UK. Tykerb is the most widely used drug of the company. In 2015, GSK has announced its acquisition of GlycoVaxyn which is a Swiss pharmaceutical company.

Test the market data and market information presented through more than 34 market data tables and 28 figures spread over 80 numbers of pages of the project report. Avail the in-depth TOC & market synopsis on “Global Breast cancer Market Research Report- Forecast To 2023”

Access Report Details @ https://www.marketresearchfuture.com/reports/global-breast-cancer-market

Segmentation:

Global breast cancer market is segmented on the basis of type into invasive ductal carcinoma, invasive lobular carcinoma and other. On the basis of treatment they are segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy and other. Chemotherapy is further segmented into antimetabolites, anthracyclines, taxanes and alkylating agents. Target therapy is further segmented into tyrosine kinase inhibitors and monoclonal antibodies Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others. On the basis of end users the market is segmented into hospital pharmacies, private pharmacies and other.

Unavailability of absolute treatment has given a wide range of platform for the development of the market. Companies are focusing on the development of new products which will be cost effective and will have minimum side effects. Some major players has adopted strategies of acquisitions and strategic alliances for the growth of the market. Moreover, competition amongst new market players is also expected to upsurge growth for breast cancer drugs market over the next seven years.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Akash Anand,

Market Research Future

+1 646 845 9312

Email: akash.anand@marketresearchfuture.com